S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
Log in
NASDAQ:PACB

Pacific Biosciences of California Stock Forecast, Price & News

$30.57
-0.61 (-1.96 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$30.15
Now: $30.57
$33.49
50-Day Range
$31.06
MA: $38.37
$51.15
52-Week Range
$2.20
Now: $30.57
$53.69
Volume6.49 million shs
Average Volume5.44 million shs
Market Capitalization$5.51 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.32
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. The company also provides consumable products, including SMRT cells, as well as various reagent kits designed for specific workflow such as template preparation to convert DNA into SMRTbell double-stranded DNA library formats including molecular biology reagents, such as ligase, buffers and exonucleases. In addition, it provides binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprises reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences has collaboration with Asuragen to develop assays for carrier screening and other applications based on SMRT sequencing technology and AmplideX PCR chemistry; Invitae Corporation focuses on the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. has collaboration with Invitae Corporation to develop ultra-high-throughput clinical whole genome sequencing platform. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.
Pacific Biosciences of California logo

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:PACB
CUSIP69404D10
Phone650-521-8000
Employees404
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$90.89 million
Book Value$0.36 per share

Profitability

Net Income$-84,130,000.00

Miscellaneous

Market Cap$5.51 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.57 out of 5 stars

Medical Sector

373rd out of 1,960 stocks

Analytical Instruments Industry

9th out of 29 stocks

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$30.57
-0.61 (-1.96 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PACB News and Ratings via Email

Sign-up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Pacific Biosciences of California (NASDAQ:PACB) Frequently Asked Questions

Is Pacific Biosciences of California a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Pacific Biosciences of California stock.
View analyst ratings for Pacific Biosciences of California
or view top-rated stocks.

What stocks does MarketBeat like better than Pacific Biosciences of California?

Wall Street analysts have given Pacific Biosciences of California a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pacific Biosciences of California wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Pacific Biosciences of California?

Pacific Biosciences of California saw a drop in short interest during the month of January. As of January 15th, there was short interest totaling 13,160,000 shares, a drop of 15.7% from the December 31st total of 15,610,000 shares. Based on an average daily trading volume, of 4,900,000 shares, the short-interest ratio is presently 2.7 days.
View Pacific Biosciences of California's Short Interest
.

When is Pacific Biosciences of California's next earnings date?

Pacific Biosciences of California is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Pacific Biosciences of California
.

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California, Inc. (NASDAQ:PACB) released its earnings results on Tuesday, February, 9th. The biotechnology company reported $0.37 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.43 by $0.06. The biotechnology company earned $27.10 million during the quarter, compared to the consensus estimate of $25.54 million. Pacific Biosciences of California had a negative trailing twelve-month return on equity of 101.30% and a negative net margin of 57.25%. Pacific Biosciences of California's revenue was up 41.9% on a year-over-year basis.
View Pacific Biosciences of California's earnings history
.

How has Pacific Biosciences of California's stock been impacted by Coronavirus?

Pacific Biosciences of California's stock was trading at $3.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PACB stock has increased by 788.7% and is now trading at $30.57.
View which stocks have been most impacted by COVID-19
.

What guidance has Pacific Biosciences of California issued on next quarter's earnings?

Pacific Biosciences of California issued an update on its fourth quarter 2020 Pre-Market earnings guidance on Monday, January, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $27-27 million, compared to the consensus revenue estimate of $23.69 million.

What price target have analysts set for PACB?

4 analysts have issued 12 month price targets for Pacific Biosciences of California's stock. Their forecasts range from $15.00 to $62.00. On average, they anticipate Pacific Biosciences of California's share price to reach $43.50 in the next twelve months. This suggests a possible upside of 42.3% from the stock's current price.
View analysts' price targets for Pacific Biosciences of California
or view top-rated stocks among Wall Street analysts.

Who are Pacific Biosciences of California's key executives?

Pacific Biosciences of California's management team includes the following people:
  • Mr. Christian O. Henry M.B.A., Pres, CEO & Director (Age 53, Pay $100.33k)
  • Dr. Michael W. Hunkapiller, Sr. Fellow & Director (Age 72, Pay $1.11M)
  • Mr. James Michael Phillips, Consultant (Age 70, Pay $498.96k)
  • Dr. Stephen Turner, Co-Founder & CTO (Age 53)
  • Ms. Susan G. Kim, Chief Financial Officer (Age 45)
  • Mr. Mark Van Oene, Chief Operating Officer (Age 47)
  • Mr. Eric E. Schaefer, VP & Chief Accounting Officer (Age 41)
  • Dr. Jonas Korlach Ph.D., Chief Scientific Officer
  • Trevin Rard, Head of Investor Relations
  • Brett Atkins J.D., Ph.D., Gen. Counsel & Corp. Sec.

What is Christian Henry's approval rating as Pacific Biosciences of California's CEO?

2 employees have rated Pacific Biosciences of California CEO Christian Henry on Glassdoor.com. Christian Henry has an approval rating of 100% among Pacific Biosciences of California's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Pacific Biosciences of California's key competitors?

What other stocks do shareholders of Pacific Biosciences of California own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Invitae (NVTA) and Tesla (TSLA).

What is Pacific Biosciences of California's stock symbol?

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Who are Pacific Biosciences of California's major shareholders?

Pacific Biosciences of California's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.39%), Jackson Square Partners LLC (7.48%), Nikko Asset Management Americas Inc. (2.79%), Sumitomo Mitsui Trust Holdings Inc. (2.48%), Price T Rowe Associates Inc. MD (1.84%) and Baker BROS. Advisors LP (1.78%). Company insiders that own Pacific Biosciences of California stock include Eric Schaefer, James Michael Phillips, Kathy Ordonez, Lucy Shapiro, Michael Hunkapiller and Susan K Barnes.
View institutional ownership trends for Pacific Biosciences of California
.

Which major investors are selling Pacific Biosciences of California stock?

PACB stock was sold by a variety of institutional investors in the last quarter, including Viking Global Investors LP, Bamco Inc. NY, Alyeska Investment Group L.P., Alyeska Investment Group L.P., Lord Abbett & CO. LLC, Abacus Planning Group Inc., Assenagon Asset Management S.A., and Pura Vida Investments LLC. Company insiders that have sold Pacific Biosciences of California company stock in the last year include Eric Schaefer, James Michael Phillips, Kathy Ordonez, Lucy Shapiro, and Michael Hunkapiller.
View insider buying and selling activity for Pacific Biosciences of California
or view top insider-selling stocks.

Which major investors are buying Pacific Biosciences of California stock?

PACB stock was purchased by a variety of institutional investors in the last quarter, including Jackson Square Partners LLC, Sei Investments Co., Price T Rowe Associates Inc. MD, Nikko Asset Management Americas Inc., BlackRock Inc., Amundi Pioneer Asset Management Inc., Sumitomo Mitsui Trust Holdings Inc., and Russell Investments Group Ltd..
View insider buying and selling activity for Pacific Biosciences of California
or or view top insider-buying stocks.

How do I buy shares of Pacific Biosciences of California?

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacific Biosciences of California's stock price today?

One share of PACB stock can currently be purchased for approximately $30.57.

How much money does Pacific Biosciences of California make?

Pacific Biosciences of California has a market capitalization of $5.51 billion and generates $90.89 million in revenue each year. The biotechnology company earns $-84,130,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

How many employees does Pacific Biosciences of California have?

Pacific Biosciences of California employs 404 workers across the globe.

What is Pacific Biosciences of California's official website?

The official website for Pacific Biosciences of California is www.pacb.com.

Where are Pacific Biosciences of California's headquarters?

Pacific Biosciences of California is headquartered at 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025.

How can I contact Pacific Biosciences of California?

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]


This page was last updated on 2/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.